Loading
A phase 2 trial of Iparomlimab and tuvonralimab in Head and neck squamous cell carcinoma, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC is a phase 2 interventional study registered as NCT07447570 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with 27 participants planned, started 2025-10-15 and due to reach its primary completion in 2027-12-31. Interventions recorded: Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy. Conditions recorded: Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody.
Linked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iparomlimab and tuvonralimab and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Iparomlimab and tuvonralimab and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/